Trial Profile
Safety, Tolerability and Efficacy of Vaginal Suppositories for Treatment of the Endometriosis
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 01 Nov 2021
Price :
$35
*
At a glance
- Drugs Afatinib (Primary) ; Axitinib (Primary) ; Linifanib (Primary)
- Indications Endometriosis
- Focus Adverse reactions
- Acronyms ELTA
- Sponsors BioGene Pharmaceutical
- 24 Oct 2021 Planned End Date changed from 28 Jan 2023 to 10 Oct 2021.
- 24 Oct 2021 Planned primary completion date changed from 2 Dec 2022 to 10 Oct 2021.
- 24 Oct 2021 Status changed from suspended to discontinued due to change in study design and sponsor.